Cargando…

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts. We examined PCSK9 trafficking in SV-589 human ski...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, My-Anh, Kosenko, Tanja, Lagace, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2014
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886665/ https://www.ncbi.nlm.nih.gov/pubmed/24296664 http://dx.doi.org/10.1194/jlr.M044156

Ejemplares similares

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
por: Sarkar, Samantha K., et al.
Publicado: (2022)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles
por: Sarkar, Samantha K., et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
por: Min, Dong-Kook, et al.
Publicado: (2015)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
por: Katsuki, Shunsuke, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
por: Seidah, Nabil G., et al.
Publicado: (2012)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding
por: Deng, Shi-jun, et al.
Publicado: (2019)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t2n70760hd27rkii5t4tbu9ki2